Palo Capital’s AbbVie ABBV Stock Holding History

Palo Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$283K	Hold	3,070	–	–	0.12%	126
2018 Q3	$290K	Sell	3,070 -88	-3%	-$8.35K	0.1%	134
2018 Q2	$293K	Buy	3,158 +88	+3%	+$8.59K	0.11%	149
2018 Q1	$291K	Hold	3,070	–	–	0.11%	152
2017 Q4	$297K	Sell	3,070 -45	-1%	-$4.24K	0.13%	113
2017 Q3	$277K	Sell	3,115 -145	-4%	-$11K	0.15%	115
2017 Q2	$236K	Hold	3,260	–	–	0.13%	115
2017 Q1	$212K	Buy	+3,260	New	+$205K	0.12%	121
2016 Q4	–	Sell	-4,598	Closed	-$290K	–	115
2016 Q3	$290K	Sell	4,598 -402	-8%	-$26K	0.2%	108
2016 Q2	$310K	Buy	+5,000	New	+$305K	0.11%	204

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Palo Capital's ABBV Position: Q4 2018 in Review

Palo Capital held its AbbVie (ABBV) position steady in Q4 2018 at 3,070 shares worth $283K. The position accounts for 0.12% of the portfolio, ranked #126.

Palo Capital first reported a position in ABBV in Q2 2016 and has held it in 10 quarters since. The position peaked at $310K in Q2 2016. 2,063 funds tracked by Wall St. Rank hold ABBV as of Q4 2018.

Palo Capital held 3,070 shares of AbbVie worth $283K as of Q4 2018.
Palo Capital left its AbbVie share count unchanged in Q4 2018.
AbbVie made up 0.12% of Palo Capital's portfolio in Q4 2018, its #126 holding.
Palo Capital first reported a position in AbbVie in Q2 2016 and has held it in 10 quarters since.
Palo Capital's AbbVie position peaked at $310K in Q2 2016.
2,063 funds tracked by Wall St. Rank held AbbVie as of Q4 2018.

Based on Palo Capital's 13F filing for Q4 2018, filed 30 Jan 2019.